Mirum Pharmaceuticals, Inc.
MIRM • NASDAQ
Mirum Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Christopher Peetz, with a market cap of $5.3B.
CEOChristopher Peetz
Next Earnings
Upcoming earnings announcement for Mirum Pharmaceuticals, Inc.
Date
Wednesday, May 6, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.40
Revenue Estimate
$148.9M
Earnings History
Past 12 earnings reports for Mirum Pharmaceuticals, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 25, 2026 | Q4 2025 | -$0.12Est: $0.04 | -400.0% | $148.9MEst: $141.6M | +5.2% |  10-K |
| Nov 4, 2025 | Q3 2025 | $0.05Est: -$0.14 | +135.7% | $133.0MEst: $131.1M | +1.5% | 10-Q |
| Aug 6, 2025 | Q2 2025 | -$0.12Est: -$0.32 | +62.5% | $127.8MEst: $108.2M | +18.1% | 10-Q |
| May 7, 2025 | Q1 2025 | -$0.30Est: -$0.27 | -11.1% | $111.6MEst: $98.4M | +13.4% | 10-Q |
| Feb 26, 2025 | Q4 2024 | -$0.49Est: -$0.25 | -96.0% | $99.4MEst: $96.6M | +2.9% | 10-K |
| Nov 12, 2024 | Q3 2024 | -$0.30Est: -$0.45 | +33.3% | $90.4MEst: $82.0M | +10.2% | 10-Q |
| Aug 7, 2024 | Q2 2024 | -$0.52Est: -$0.47 | -10.6% | $77.9MEst: $75.3M | +3.5% | 10-Q |
| May 8, 2024 | Q1 2024 | -$0.54Est: -$0.48 | -12.5% | $69.2MEst: $70.2M | -1.4% | 10-Q |
| Feb 28, 2024 | Q4 2023 | -$0.66Est: -$0.24 | -175.0% | $69.6MEst: $67.8M | +2.6% | 10-K |
| Nov 2, 2023 | Q3 2023 | -$0.57Est: -$0.65 | +12.3% | $47.7MEst: $37.1M | +28.6% | — |
| Aug 3, 2023 | Q2 2023 | -$1.94Est: -$0.81 | -139.5% | $37.5MEst: $30.0M | +25.0% | 10-Q |
| May 4, 2023 | Q1 2023 | -$0.80Est: -$0.94 | +14.9% | $31.6MEst: $28.7M | +10.1% | — |